Jéssica Adriana Jesus (Jéssica A Jesus)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Plasmodium Falciparum

Replacement Therapy

Mesenchymal Stem Cells

Top Venues

Pharmaceuticals (Basel, Switzerland)

Journal of immunology research

Pathogens (Basel, Switzerland)

Evidence-based complementary and alternative medicine : eCAM

This page only lists publications with an associated author ORCID identifier.

Publications

Jéssica Adriana Jesus, Thays Nicolli Fragoso da Silva, Ilza Maria Oliveira Sousa, Aurea Favero Ferreira, Marcia Dalastra Laurenti, Paulo Cardoso da Costa, Domingos de Carvalho Ferreira, Luiz Felipe Domingues Passero
Nanostructured Lipid Carriers as Robust Systems for Lupeol Delivery in the Treatment of Experimental Visceral Leishmaniasis. Pharmaceuticals (Basel, Switzerland) 16 (12) (2023)
Jéssica Adriana Jesus, Thays Nicolli Fragoso da Silva, Ilza Maria Oliveira Sousa, Aurea Favero Ferreira, Marcia Dalastra Laurenti, Paulo Cardoso da Costa, Domingos de Carvalho Ferreira, Luiz Felipe Domingues Passero
Nanostructured Lipid Carriers as Robust Systems for Lupeol Delivery in the Treatment of Experimental Visceral Leishmaniasis. Pharmaceuticals (Basel, Switzerland) 16 (12) (2023)
Jéssica Adriana Jesus, Marcia Dalastra Laurenti, Matheus Lopes Silva, João Henrique Ghilardi Lago, Luiz Felipe Domingues Passero
Leishmanicidal Activity and Ultrastructural Changes of Maslinic Acid Isolated from Hyptidendron canum. Evidence-based complementary and alternative medicine : eCAM 2021 (2021)
Adriana Bezerra-Souza, Jéssica Adriana Jesus, Marcia Dalastra Laurenti, Aikaterini Lalatsa, Dolores R Serrano, Luiz Felipe Domingues Passero
Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis. Journal of immunology research 2021 (2021)
Jéssica Adriana Jesus, Thays Nicolli Fragoso da Silva, Eduardo Seiji Yamamoto, João Henrique Ghilardi Lago, Marcia Dalastra Laurenti, Luiz Felipe Domingues Passero
Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis. Pathogens (Basel, Switzerland) 9 (10) (2020)